At MaxCyte, we share your passion for the discovery, development, and manufacturing of next generation therapies, harnessing the power of living cells to transform lives.
We know that every research journey is full...
Read More
At MaxCyte, we share your passion for the discovery, development, and manufacturing of next generation therapies, harnessing the power of living cells to transform lives.
We know that every research journey is full of challenges, but we believe that transfecting cells shouldn’t be one of them. With over 20 years of cell engineering expertise using our best-in-class electroporation technology, we’ve perfected the art of the cell-engineering workflow. We want to share this with you to enable your pioneering research and help you to chart your most direct course to success.
MaxCyte is the technology of choice for cell-engineering experts, driving a new generation of cell-based therapies. We have collaborated in many clinical trials driven by leaders in pharma and biotech to develop treatments for an expanding range of indications, including cancer, central nervous system disorders, and rare genetic diseases.
Are low gene editing efficiency or gene expression levels preventing your research from advancing? Is your transfection method killing your cells? Are you struggling to reproduce your initia...
Register to learn more about how to rapidly and reproducibly drive your developmental efforts forward by leveraging MaxCyte’s flow electroporation technology. Labs adopt this scalable...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...
Date: October 19, 2022 Time: 6:00am (PDT), 9:00am (EDT), 2:00pm (CEST) It is important that clinical drug candidates not only have appropriate affinity and target specificity, but also have...
Date: May 24, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Recent breakthroughs in autologous cellular therapies have generated tremendous excitement for the industry; however, thes...
Date: November 30, 2021 Time: 8:00am (PDT), 11:00am (EDT) The DNA Vector Lab at the German Cancer Research Center (DKFZ) has developed Nano-S/MARt (nS/MARt), a novel DNA Vector platform that...
DATE: September 17, 2020 TIME: 8:00am PT CRISPR-Cas9 has tremendous potential as a therapeutic tool for treating human diseases. However, prolonged expression of the nuclease and gRNA from v...
DATE: June 23, 2020 TIME: 6:00 am PDT, 9:00 am EDT In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies t...